Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions.

Created on 04 Nov 2026

Authors

Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni

Published in

Cancer. Volume 132. Issue 22. Nov 15, 2026.

Abstract

Anti-B cell maturation antigen (BCMA) therapies, including antibody-drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs and the main reasons behind loss of response and treatment resistance. Moreover, available safety and efficacy information on approved agents (i.e., teclistamab, elranatamab, and linvoseltamab) are described, focusing on the most relevant treatment-related toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias, and infections, and established approaches for their monitoring and management. Furthermore, available data on active trials evaluating the use of bsAbs in combination with other agents and/or in earlier lines of therapy are discussed, as well as emerging data on novel anti-BCMA bsAbs in clinical development, such as etentamig. Finally, the use of bsAbs beyond multiple myeloma has been explored by reviewing clinical trials and real-world experiences in other monoclonal gammopathies (e.g., smoldering multiple myeloma and light-chain amyloidosis) or other conditions, such as autoimmune diseases. Overall, the objective of this review was to provide a comprehensive overview on the role of BCMA-targeting bsAbs while discussing future developments in this field, including their use across different settings and combinations strategies, as well as the ongoing efforts to improve safety and tolerability through the implementation of specific guidelines for toxicity management.

PMID:
42980050
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement